Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - INTEGRAMED AMERICA INC | form8k02112010.htm |
| EX-1.1 - UNDERWRITING AGREEMENT - INTEGRAMED AMERICA INC | exhibit1_1.htm |
| EX-10.1 - PURCHASE AGREEMENT - INTEGRAMED AMERICA INC | exhibit10.htm |
News Announcement
INTEGRAMED
PRICES 2.5 MILLION SHARE
COMMON
STOCK OFFERING AT $7.50 PER SHARE
Purchase, NY – February 12, 2010
-- IntegraMed America, Inc. (NASDAQ: INMD) today announced that it has
priced a public offering of 2,500,000 shares of its common stock at a price to
the public of $7.50 per share, of which 2,000,000 shares are being offered
through the underwriters named below and 500,000 shares are being offered
directly by IntegraMed to IAT Reinsurance Company Ltd., IntegraMed’s largest
stockholder.
The
approximately $17 million of net proceeds, after deducting underwriting
discounts, commissions and expected offering expenses payable by IntegraMed, are
intended to be used to accelerate the addition of new partner fertility centers,
to accelerate the pace of new vein clinic openings in 2010, or for general
working capital and other corporate purposes. The offering is
expected to close on or about February 18, 2010, subject to the satisfaction of
customary closing conditions.
The
underwriters have been granted a 30-day option to purchase up to an additional
300,000 shares to cover over-allotments, if any.
Piper
Jaffray & Co. acted as book-running manager and Dougherty & Company LLC
acted as co-manager for the offering. The offering is being made
pursuant to an effective registration statement filed with the Securities and
Exchange Commission. Copies of the final prospectus relating to the
offering may be obtained from the Securities and Exchange Commission website at
http://www.sec.gov or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite
800, Minneapolis, MN 55402 or by calling 1-800-747-3924.
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of, the securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction.
About
IntegraMed America, Inc.
IntegraMed
America, Inc. manages highly specialized outpatient facilities in emerging,
technology-based, niche medical markets and is a leading manager of fertility
centers and vein care clinics in the United States. IntegraMed
supports its provider networks with clinical and business information systems,
marketing and sales, facilities and operations management, finance and
accounting, human resources, legal, risk management and quality assurance
services. IntegraMed also offers treatment-financing programs for
self-pay patients.
This
press release contains certain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act. IntegraMed cautions
that these forward-looking statements are subject to numerous assumptions, risks
and uncertainties, which may change over time. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may cause
the actual results, performance or achievements of IntegraMed to be materially
different from those expressed or implied by such forward-looking statements.
Such factors include, among other things, IntegraMed’s ability to satisfy all
required closing conditions of the offering and other factors referenced herein.
Further information on the factors and risks that could affect IntegraMed’s
business, financial condition and results of operations is contained in
IntegraMed’s filings with the Securities and Exchange Commission, which are
available at http://www.sec.gov. All information in this press
release is as of February 12, 2010, and IntegraMed undertakes no duty to update
this information.
# # #
CONTACT:
|
Investors:
|
Media/Investors:
|
|
John
W. Hlywak, Jr., EVP and CFO
|
Norberto
Aja, David Collins
|
|
IntegraMed
America, Inc.
|
Jaffoni
& Collins
|
|
jhlywak@integramed.com
|
inmd@jcir.com
|
|
914-251-4143
|
212-835-8500
|